title: Registered report: the CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
abstract: The Willingham et al., 2012, published in PNAS in 2012. The key experiments being replicated are those reported in Figure 6A-C and Table S4. In these experiments, Willingham et al., 2012 test the safety and efficacy of anti-CD47 antibody treatment in immune competent mice utilizing a syngeneic model of mammary tumor growth in FVB mice. The Reproducibility Project: Cancer Biology is a collaboration between the eLife.
authors.affiliation: Noble Life Sciences, Gaithersburg, Maryland, United States.
authors.forename: Denise
authors.initials: D
authors.lastname: Chroscinski
authors.affiliation: Harvard Stem Cell Institute, Cambridge, Massachusetts, United States.
authors.forename: Nimet
authors.initials: N
authors.lastname: Maherali
authors.affiliation: University of Virginia, Charlottesville, United States.
authors.forename: Erin
authors.initials: E
authors.lastname: Griner
mesh_terms: D000818:Animals; D000943:Antigens, Differentiation / Q000378:metabolism*; D051928:CD47 Antigen / Q000378:metabolism*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D011485:Protein Binding; D011971:Receptors, Immunologic / Q000378:metabolism*
chemical_list: D000943:Antigens, Differentiation; D051928:CD47 Antigen; D011971:Receptors, Immunologic; C501920:SIRPA protein, human
keywords: CD47; Reproducibility Project: Cancer Biology; human biology; medicine; methodology; mouse; targeted therapy